Adrenomedullin is a biological marker of heart failure: review of modern literature Amina M. Alieva*1, Natalia

Cover Page

Cite item

Full Text

Abstract

It has been proven that in patients with heart failure (HF), there is an increased level of adrenomedullin (ADM) in plasma. Biomarker indices correlate with the severity of hemodynamic dysfunction, as well as with neurohumoral indices, which are activated depending on the severity of congestive circulatory failure. In addition, the expression of the ADM gene in the heart and kidneys is increased in experimental and clinical HF. A small number of studies have examined the effect of ADM infusion. These studies have generally shown that hormone infusion has beneficial hemodynamic effects and promotes the maintenance/improvement of renal function, but most of the studies have been short-lived. The available results suggest that increasing ADM levels reduce the negative effects of vasoconstriction and sodium retention. A better understanding of the role of a biological marker in congestive circulatory failure may lead to the development of drugs that target ADM receptors.

About the authors

Amina M. Alieva

Pirogov Russian National Research Medical University

Author for correspondence.
Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-5416-8579

Cand. Sci. (Med.)

Russian Federation, Moscow

Natalia V. Teplova

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-7181-4680

D. Sci. (Med.), Prof.

Russian Federation, Moscow

Kira V. Voronkova

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru

D. Sci. (Med.)

Russian Federation, Moscow

Tatyana V. Pinchuk

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0002-7877-4407

Cand. Sci. (Med.)

Russian Federation, Moscow

Ramiz K. Valiev

Loginov Moscow Clinical Scientific Center

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0003-1613-3716

Cand. Sci. (Med.)

Russian Federation, Moscow

Lidia M. Shnakhova

Sechenov First Moscow State Medical University (Sechenov University)

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0003-3000-0987

therapist

Russian Federation, Moscow

Alik M. Rahaev

Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0001-9601-1174

D. Sci. (Med.), Main Bureau of Medical and Social Expertise in the Kabardino-Balkarian Republic

Russian Federation, Nalchik

Igor G. Nikitin

Pirogov Russian National Research Medical University

Email: amisha_alieva@mail.ru
ORCID iD: 0000-0003-1699-0881

D. Sci. (Med.), Prof.

Russian Federation, Moscow

References

  1. Tsao CW, Lyass A, Enserro D, et al. Temporal trends in the incidence of and mortality associated with heart failure with preserved and reduced ejection fraction. JACC Heart Fail. 2018;6(8):678-85. doi: 10.1016/j.jchf.2018.03.006
  2. Фомин И.В. Хроническая сердечная недостаточность в Российской Федерации: что сегодня мы знаем и что должны делать. Российский кардиологический журнал. 2016;8:7-13 [Fomin IV. Chronic heart failure in Russian Federation: what do we know and what to do. Russian Journal of Cardiology. 2016;8:7-13 (in Russian)]. doi: 10.15829/1560-4071-2016-8-7-13
  3. Maggioni AP, Dahlström U, Filippatos G, et al. EURObservational Research Programme: regional differences and 1-year follow-up results of the Heart Failure Pilot Survey (ESC-HF Pilot). Eur J Heart Fail. 2013;15(7):808-17. doi: 10.1093/eurjhf/hft050
  4. Meijers WC, de Boer RA. Common risk factors for heart failure and cancer. Cardiovasc Res. 2019;115(5):844-53. doi: 10.1093/cvr/cvz035
  5. Алиева А.М., Пинчук Т.В., Алмазова И.И., и др. Клиническое значение определения биомаркера крови ST2 у больных с хронической сердечной недостаточностью. Consilium Medicum. 2021;23(6):522-6 [Alieva AM, Pinchuk TV, Almazova II, et al. The clinical significance of determining the ST2 blood biomarker in patients with chronic heart failure. Consilium Medicum. 2021;23(6):522-6 (in Russian)]. doi: 10.26442/20751753.2021.6.200606
  6. Алиева А.М., Резник Е.В., Гасанова Э.Т., и др. Клиническое значение определения биомаркеров крови у больных с хронической сердечной недостаточностью. Архивъ внутренней медицины. 2018;8(5):333-45 [Alieva AM, Reznik EV, Hasanova ET, et al. Clinical value of blood biomarkers in patients with chronic heart failure. The Russian Archives of Internal Medicine. 2018;8(5):333-45 (in Russian)]. doi: 10.20514/2226-6704-2018-8-5-333-345
  7. Kitamura K, Kangawa K, Kawamoto M, et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun. 1993;192(2):553-60. doi: 10.1006/bbrc.1993.1451
  8. Ishimitsu T, Kojima M, Kangawa K, et al. Genomic structure of human adrenomedullin gene. Biochem Biophys Res Commun. 1994;203(1):631-9. doi: 10.1006/bbrc.1994.2229
  9. Betowski J, Jamroz A. Adrenomedullin – what do we know 10 years since its discovery? Pol J Pharmacol. 2004;56:5-27.
  10. Patel P, Mishra A, Sheikh AA, et al. Adrenomedullin: a novel peptide hormone. A review. J Pharmacogn Phytochem. 2017;6(6):2068-73.
  11. Voors AA, Kremer D, Geven C, et al. Adrenomedullin in heart failure: pathophysiology and therapeutic application. Eur J Heart Fail. 2019;21(2):163-71. doi: 10.1002/ejhf.1366
  12. Schönauer R, Els-Heindl S, Beck-Sickinger AG. Adrenomedullin – new perspectives of a potent peptide hormone. J Pept Sci. 2017;23(7-8):472-85. doi: 10.1002/psc.2953
  13. Dschietzig T, Azad HA, Asswad L, et al. The adrenomedullin receptor acts as clearance receptor in pulmonary circulation. Biochem Biophys Res Commun. 2002;294(2):315-8. doi: 10.1016/S0006-291X(02)00474-6
  14. Holmes D, Corr M, Thomas G, et al. Protective effects of intermedin/adrenomedullin-2 in a cellular model of human pulmonary arterial hypertension. Peptides. 2020;126:170267. doi: 10.1016/j.peptides.2020.170267
  15. Jougasaki M, Wei CM, McKinley LJ, Burnett JC Jr. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation. 1995;92(3):286-9. doi: 10.1161/01.cir.92.3.286
  16. Nishikimi T, Nakagawa Y. Adrenomedullin as a biomarker of heart failure. Heart Fail Clin. 2018;14(1):49-55. doi: 10.1016/j.hfc.2017.08.006
  17. Piek A, Du W, de Boer RA, Silljé HHW. Novel heart failure biomarkers: why do we fail to exploit their potential? Crit Rev Clin Lab Sci. 2018;55(4):246-63. doi: 10.1080/10408363.2018.1460576
  18. Gegenhuber A, Struck J, Dieplinger B, et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail. 2007;13(1):42-9. doi: 10.1016/j.cardfail.2006.09.004
  19. Maisel A, Mueller C, Nowak R, et al. Mid-region pro-hormone markers for diagnosis and prognosis in acute dyspnea: results from the BACH (Biomarkers in Acute Heart Failure) trial. J Am Coll Cardiol. 2010;19:2062-76. doi: 10.1016/j.jacc.2010.02.025
  20. Weber J, Sachse J, Bergmann S, et al. Sandwich immunoassay for bioactive plasma adrenomedullin. J Appl Lab Med. 2017;2(2):222-33. doi: 10.1373/jalm.2017.023655
  21. Self WH, Storrow AB, Hartmann O, et al. Plasma bioactive adrenomedullin as a prognostic biomarker in acute heart failure. Am J Emerg Med. 2016;34(2):257-62. doi: 10.1016/j.ajem.2015.10.033
  22. Tolppanen H, Rivas-Lasarte M, Lassus J, et al. Adrenomedullin: a marker of impaired hemodynamics, organ dysfunction, and poor prognosis in cardiogenic shock. Ann Intensive Care. 2017;7(1):1-10. doi: 10.1186/s13613-016-0229-2
  23. Ter Maaten JM, Kremer D, Demissei BG, et al. Bio-adrenomedullin as a marker of congestion in patients with new-onset and worsening heart failure. Eur J Heart Fail. 2019;21(6):732-43. doi: 10.1002/ejhf.1437
  24. Pandhi P, Ter Maaten JM, Emmens JE, et al. Clinical value of pre-discharge bio-adrenomedullin as a marker of residual congestion and high risk of heart failure hospital readmission. Eur J Heart Fail. 2020;22(4):683-91. doi: 10.1002/ejhf.1693
  25. Мясоедова Е.И. Уровень проадреномедуллина при хронической сердечной недостаточности ишемического генеза: ассоциации с клиническими проявлениями. Бюллетень сибирской медицины. 2019;18(3):81-9 [Myasoedova EI. The level of proadrenomedullin in chronic heart failure of ischemic genesis: associations with clinical manifestations. Bulletin of Siberian Medicine. 2019;18(3):81-9 (in Russian)]. doi: 10.20538/1682-0363-2019-3-81-89
  26. Morbach C, Marx A, Kaspar M, et al. Prognostic potential of midregional pro-adrenomedullin following decompensation for systolic heart failure: comparison with cardiac natriuretic peptides. Eur J Heart Fail. 2017;19(9):1166-75. doi: 10.1002/ejhf.859
  27. Попов Д.А., Хрусталев А.А. Прогностическая ценность новых биомаркеров у детей первого года жизни с врожденными пороками сердца в периоперационном периоде. Лабораторная служба. 2019;8(4):13-21 [Popov DA, Khrustalev AA. Prognostic value of new biomarkers in newborns and children with congenital heart disease. Laboratory service. 2019;8(4):13-21 (in Russian)]. doi: 10.17116/labs2019804113
  28. Niu P, Shindo T, Iwata H, et al. Accelerated cardiac hypertrophy and renal damage induced by angiotensin II in adrenomedullin knockout mice. Hypertens Res. 2003;26(9):731-6. doi: 10.1291/hypres.26.731
  29. Nishikimi T, Yoshihara F, Horinaka S, et al. Chronic administration of adrenomedullin attenuates transition from left ventricular hypertrophy to heart failure in rats. Hypertension. 2003;42(5):1034-41. doi: 10.1161/01.HYP.0000097604.64716.D2
  30. Okumura H, Nagaya N, Itoh T, et al. Adrenomedullin infusion attenuates myocardial ischemia/reperfusion injury through the phosphatidylinositol 3-kinase/Akt-dependent pathway. Circulation. 2004;109(2):242-8. doi: 10.1161/01.CIR.0000109214.30211.7C
  31. Nakamura R, Kato J, Kitamura K, et al. Adrenomedullin administration immediately after myocardial infarction ameliorates progression of heart failure in rats. Circulation. 2004;110(4):426-31. doi: 10.1161/01.CIR.0000136085.34185.83
  32. Niu P, Shindo T, Iwata H, et al. Protective effects of endogenous adrenomedullin on cardiac hypertrophy, fibrosis, and renal damage. Circulation. 2004;109(14):1789-94. doi: 10.1161/01.CIR.0000118466.47982.CC
  33. Looi YH, Kane KA, McPhaden AR, Wainwright CL. Adrenomedullin acts via nitric oxide and peroxynitrite to protect against myocardial ischaemia-induced arrhythmias in anaesthetized rats. Br J Pharmacol. 2006;148(5):599-609. doi: 10.1038/sj.bjp.0706771
  34. Yoshizawa T, Takizawa S, Shimada S, et al. Effects of adrenomedullin on doxorubicin-induced cardiac damage in mice. Biol Pharm Bull. 2016;39(5):737-46. doi: 10.1248/bpb.b15-00832
  35. Li LL, Peng C, Zhang M, et al. Mesenchymal stem cells overexpressing adrenomedullin improve heart function through antifibrotic action in rats experiencing heart failure. Mol Med Rep. 2018;17(1):1437-44. doi: 10.3892/mmr.2017.8049
  36. Nishikimi T, Karasawa T, Inaba C, et al. Effects of Long-Term Intravenous Administration of Adrenomedullin (AM) Plus hANP Therapy in Acute Decompensated Heart Failure A Pilot Study. Circ J. 2009;73(5):892-8. doi: 10.1253/circj.cj-08-0487
  37. Nagaya N, Satoh T, Nishikimi T, et al. Hemodynamic, renal, and hormonal effects of adrenomedullin infusion in patients with congestive heart failure. Circulation. 2000;101(5):498-503. doi: 10.1161/01.cir.101.5.498
  38. Geven C, Bergmann A, Kox M, Pickkers P. Vascular effects of adrenomedullin and the anti-adrenomedullin antibody adrecizumab in sepsis. Shock. 2018;50(2):132-40. doi: 10.1097/SHK.0000000000001103
  39. Geven C, van Lier D, Blet A, et al. Safety, tolerability and pharmacokinetics/pharmacodynamics of the adrenomedullin antibody adrecizumab in a first-in-human study and during experimental human endotoxaemia in healthy subjects. Br J Clin Pharmacol. 2018;84(9):2129-41. doi: 10.1111/bcp.13655

Copyright (c) 2022 Eco-Vector

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies